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Abstract
Background: Burkholderia pseudomallei infection (melioidosis) is an important cause of community-acquired Gram-negative
sepsis in Northeast Thailand, where it is associated with a ,40% mortality rate despite antimicrobial chemotherapy. We
showed in a previous cohort study that patients taking glyburide ( = glibenclamide) prior to admission have lower mortality
and attenuated inflammatory responses compared to patients not taking glyburide. We sought to define the mechanism
underlying this observation in a murine model of melioidosis.
Methods: Mice (C57BL/6) with streptozocin-induced diabetes were inoculated with ,66102 cfu B. pseudomallei
intranasally, then treated with therapeutic ceftazidime (600 mg/kg intraperitoneally twice daily starting 24 h after
inoculation) in order to mimic the clinical scenario. Glyburide (50 mg/kg) or vehicle was started 7 d before inoculation
and continued until sacrifice. The minimum inhibitory concentration of glyburide for B. pseudomallei was determined by
broth microdilution. We also examined the effect of glyburide on interleukin (IL) 1b by bone-marrow-derived
macrophages (BMDM).
Results: Diabetic mice had increased susceptibility to melioidosis, with increased bacterial dissemination but no effect was
seen of diabetes on inflammation compared to non-diabetic controls. Glyburide treatment did not affect glucose levels but
was associated with reduced pulmonary cellular influx, reduced bacterial dissemination to both liver and spleen and
reduced IL1b production when compared to untreated controls. Other cytokines were not different in glyburide-treated
animals. There was no direct effect of glyburide on B. pseudomallei growth in vitro or in vivo. Glyburide directly reduced the
secretion of IL1b by BMDMs in a dose-dependent fashion.
Conclusions: Diabetes increases the susceptibility to melioidosis. We further show, for the first time in any model of sepsis,
that glyburide acts as an anti-inflammatory agent by reducing IL1b secretion accompanied by diminished cellular influx and
reduced bacterial dissemination to distant organs. We found no evidence for a direct effect of glyburide on the bacterium.
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Introduction
Melioidosis is a severe community-acquired sepsis in Southeast
Asia, caused by infection with Burkholderia pseudomallei, an
environmental soil saprophyte [1]. Its northern-most extent is
southern China and its southern-most extent is northern Australia.
B. pseudomallei has a myriad of clinical presentations ranging from
acute pneumonia to chronic skin abscess [1]. More than half of
patients are bacteremic, around half have pneumonia and
mortality approaches 40% [2]. B. pseudomallei has recently been
classed a tier 1 bioterror threat agent [3] and is a good clinical
model of Gram-negative sepsis [4].
Diabetes is the most commonly identified risk factor for sepsis
in general [5] and melioidosis in particular [2], where it occurs
in around a third of all melioidosis patients. This is consistent
with the fact that diabetes is associated with an impaired host
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response to B. pseudomallei: specifically, it impairs cytokine
responses [6–8] and macrophage killing of intracellular B.
pseudomallei [9].
Paradoxically, melioidosis patients with a pre-admission diag-
nosis of diabetes have a lower risk of mortality than patients
without diabetes, which appears to contradict our current
knowledge of the effect of diabetes on the host. We have shown
previously, in a cohort study of 1,160 patients, that this reduction
in risk is associated with glyburide use, and does not appear to be a
characteristic of diabetes itself [2].
Glyburide USAN ( = glibenclamide rINN) is a KATP-
channel blocker and broad-spectrum ATP-binding cassette
(ABC) transporter inhibitor used to treat type 2 diabetes. It
costs less than USD 0.10 per dose and appears on the World
Health Organization (WHO) model list of essential medicines
[10]. Glyburide is readily available and is also one of the
most frequently prescribed oral drugs for type 2 diabetes
worldwide.
The relevant pharmacological mechanism of glyburide in
diabetes is the inhibition of KATP-channels in pancreatic b-cells,
which leads to the stimulation of insulin secretion. There is,
however, evidence from experimental models that glyburide also
has a wide range of anti-inflammatory effects [11]. We confirmed
the anti-inflammatory effect of glyburide in a whole blood gene
expression study of melioidosis patients on glyburide, however, the
anti-inflammatory effect we saw was general, without any one
pathway predominating [2].
In this study, we used an experimental model of melioidosis to
provide insights into mechanisms underlying the effect of
glyburide on inflammation, the best described of which is an
inhibitory effect on the host inflammasome, an intracellular
protein complex present in macrophages that activates caspase 1
and cleaves pro-IL1b and pro-IL18 to their active forms when
presented with an appropriate inflammatory stimulus [12]. We
show for the first time, in an experimental model of sepsis, that
glyburide acts as an anti-inflammatory agent by reducing IL1b
secretion, cellular infiltration into the lungs and bacterial
dissemination to distant organs.
Methods
Ethics
Mouse experiments were performed at the Academic Medical
Center (AMC), University of Amsterdam and were approved by
the animal experimentation committee of the AMC (number
DIX101725). Mouse experiments were performed in accordance
with Dutch law (Wet op de dierproven 1996) and European
Council directive (86/609/EEC). Bone marrow-derived macro-
phage experiments were performed at the Friedrich Loeffler
Institut fu¨r Medizinische Mikrobiologie, Universita¨tsmedizin
Greifswald, in compliance with the relevant laws.
Murine models of diabetes and melioidosis
The C57Bl/6J substrain (Jackson Laboratories) is a model for
diet-induced type 2 diabetes, because it carries a spontaneous
17.8 kb deletion in the nicotinamide nucleotide transhydrogenase
gene, Nnt, that appeared in the Jackson Laboratories colony some
time between 1951 and 1970 [13,14]. We therefore elected to use
the C57Bl/6N (Charles River) substrain for all mouse experiments
because that substrain has an intact Nnt gene [15]. There is no
consensus in the literature over which mouse strain best models
the pathology seen in human disease, and both BALB/c and
C57Bl/6 mice have been used [16–19]. It has been described by
multiple authors that killing of intracellular B. pseudomallei by
BALB/c mice is deficient compared to C57Bl/6 mice [16,20–23],
and that this failure to clear the bacterium results in continued
stimulation of type 1 cytokine secretion [21]. The reason for this is
not known, but Watanabe et al. have reported that BALB/c
macrophages express lower levels of the lysosomal enzyme, b-
glucuronidase, in response to macrophage-activating lipopeptide-2
(a synthetic TLR2 ligand) and to E. coli LPS when compared to
C57Bl/6 macrophages [24]. In humans, b-glucuronidase defi-
ciency manifests as Sly syndrome, or mucopolysaccharidosis type
VII. The potential association of the BALB/c mouse with an
inherited human disease should prompt caution in the interpre-
tation of experiments conducted using this strain.
We used a streptozocin model of diabetes, because that model
permits a diabetic phenotype to be induced on any background, at
any time, and the cohort become diabetic synchronously [25,26].
Streptozocin 6 mg/ml (Sigma-Aldrich, Zwijndrecht, The Nether-
lands) was prepared fresh every day in citrate buffer, then passed
through a 0.2 mm polyethersulphone filter (VWR 514-0073) and
administered intraperitoneally within 60 minutes of preparation.
Citrate buffer 50 mmol/l was made by adding 2.76 g sodium
citrate (Merck) and 3.28 g citric acid monohydrate (Merck) to
500 ml de-ionised water, then adjusting the pH to 4. Streptozocin
solutions are not stable for longer than 12 h and were therefore
made up freshly each day [27]. Specified pathogen-free 10-week-
old C57Bl/6NCrl mice (Charles River) were made diabetic by
injection with streptozocin 60 mg/kg daily for five days [26];
controls were injected with vehicle. Plasma glucose was checked
weekly (Bayer Contour meter) by cheek puncture [28]. For 10-
week-old mice not treated with streptozocin, glucose was
8.7561.52 mM (mean6standard deviation, N= 48) and for 16-
week-old mice, 9.3061.64 mM. We defined diabetes as a plasma
glucose $16.7 mM (N=48) [26].
B. pseudomallei 1026b is a clinical isolate collected in 1993 from a
29-year-old Thai female rice farmer with bacteremia, soft tissue,
cutaneous lesions, septic arthritis and splenic abscesses [29]. Mice
were infected with ,66102 B. pseudomallei 1026b intranasally 4–5
weeks after streptozocin treatment (the LD50 for this model is
,16102 cfu [30]). This model of melioidosis has been described in
detail elsewhere [19,31]. In order to mimic our previous clinical
Author Summary
Burkholderia pseudomallei infection (also called melioido-
sis) is a common cause of bacterial infection in Northeast
Thailand, where the mortality rate is 43% despite
appropriate antibiotic treatment. We showed previously
that patients taking glyburide ( = glibenclamide) prior to
admission have lower mortality rates and lower levels of
inflammation in the blood. In this study, we used a mouse
model to better understand the mechanism underlying
this observation. In this study, we used a mouse model of
diabetes and infected the mice with B. pseudomallei. Half
the mice were treated with glyburide and half were not.
We also performed in vitro experiments to find the
minimum concentration of glyburide that would inhibit
the growth of B. pseudomallei. We found that glyburide
treatment was associated with reduced inflammation (as
measured by the flow of cells into the lungs and by
interleukin-1b production) and reduced spread of the
bacterium to liver and spleen when compared to
untreated controls. There was no direct effect of glyburide
on B. pseudomallei growth in vitro or in vivo. Because the
effect of glyburide is on the host and not on the
bacterium, it is possible that this effect will be seen in
other causes of sepsis, not just melioidosis.
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cohort study, all animals were treated with full-dose antibiotics. All
animals received ceftazidime 600 mg/kg (GlaxoSmithKline,
Brentford, England) intraperitoneally starting 24 h after inocula-
tion and continued twice daily until sacrifice [32].
Glyburide 50 mg/kg (Sigma-Aldrich, Zwijndrecht, The Nether-
lands) or vehicle was administered intraperitoneally once daily
starting 7 days before inoculation and continued until sacrifice.
Glyburide solutions were prepared in 20% dimethylsulfoxide
(DMSO); control mice were given 20% DMSO. This dose of
glyburide was chosen because it is equivalent to the highest human
dose (20 mg daily to a 50 kg Thai male) after taking into account
differences in pharmacokinetics (human tK<8 hours, mouse
tK<1 hour) [12].
Animals were allowed ad libitum access to food (801733 CRM,
Tecnilab-BMI) and water, and were group-housed in polycarbon-
ate cages with 12-hour light/dark cycles, temperature 18–22uC,
humidity 40–65%. Eight animals from each group were sacrificed
48, 72 and 96 hours after inoculation. At sacrifice, mice were
sedated with ketamine/medetomidine intraperitoneally (12.5 mg/
20 mg per 100 g weight), then exsanguinated by cardiac puncture.
Death was confirmed by cutting the diaphragm. Glucose
measurements were obtained prior to sedation as medetomidine
itself elevates glucose concentrations. The left lung was lavaged
with three 300 ml aliquots of sterile 0.9% saline then collected for
culture. Left lung, liver and spleen were homogenized in sterile
saline in a ratio of 1 g organ to 4 ml of saline. Organ
homogenates, blood and bronchoalveolar lavage fluid (BALF)
were plated onto blood agar in serial dilutions to quantify bacterial
burdens. The remaining lung homogenate was incubated for
30 minutes with Greenberger lysis buffer then centrifuged at 6506
g for 10 minutes. The supernatant was passed through a 0.2 mm
filter (PVDF, Millex-GV, Millipore) to remove viable bacteria,
then stored at 220uC for cytokine measurements. Heparinized
blood was centrifuged at 7006 g for 10 minutes; the plasma was
filtered and stored at 220uC pending analysis.
Assays
Creatinine was measured with a commercial available kit
(Sigma-Aldrich, St. Louis, MO) using a Hitachi analyzer
(Boehringer Mannheim, Mannheim, Germany) according to the
manufacturers’ instructions. In lung homogenates and BALF,
interleukin (IL) 1b, IL6, IL10, CXCL5 (LIX) and tumor necrosis
factor-a (TNFa) were measured by sandwich ELISA (R&D
Systems, Oxford, England). Cytokine levels in plasma were
measured by particle immunoassay (mouse inflammation cyto-
metric bead array, BD Biosciences, San Jose, California) because
of limited sample quantity. Protein concentrations were measured
using the DCTM protein assay (Bio-Rad, Hercules, California).
Glyburide minimum inhibitory concentration
The minimum inhibitory concentration of glyburide was
established by broth microdilution and the protocol was adapted
from the CLSI guidelines for microdilution assays of non-fastidious
organisms [33]. The positive control was sulfamethoxazole
512 mg/ml and the negative control was DMSO 1%. Glyburide
was assayed in doubling dilutions from 0.1 to 1000 mM. The
culture medium was cation-adjusted Mueller-Hinton broth (Sig-
ma-Aldrich). Antimicrobial solution 50 ml and inoculum 50 ml (B.
pseudomallei final concentration 56105 cfu/ml) were pipetted into
each well of a flat-bottomed 96-well plate. The final concentration
of DMSO in every well was 1%. Cultures were incubated at 37uC
(5% carbon dioxide) for 18 hours. Growth was defined as a pellet
$2 mm or turbidity on visual inspection. The MIC of glyburide
was read as the lowest concentration of glyburide that inhibited
the growth of B. pseudomallei.
Bone marrow-derived macrophages
Bone marrow-derived macrophages were generated as previ-
ously described [23]. In brief, specified pathogen-free C57Bl/6
mice were anesthetized with sevoflurane then sacrificed by cervical
dislocation. Tibias and femurs were removed under aseptic
conditions; bone marrow was flushed out with Dulbecco’s
phosphate-buffered saline (PBS) (Invitrogen, Carlsbad, California)
then centrifuged at 1506g for 10 minutes. Cells were resuspended
in RPMI 1640 (Invitrogen) containing Panexin BMM 5% v/v
(PAN Biotech, Aidenbach, Germany), 2 ng/ml recombinant
murine GM-CSF (PAN Biotech) and 50 mM 2-mercaptoethanol.
Cells were cultured for 10 days at 37uC and 5% carbon dioxide.
Cultures were washed with PBS to remove non-adherent cells.
Adherent cells were then detached with Trypsin-EDTA (PAA
Laboratories, Pasching, Austria) and by scraping. Viable cells were
counted in a Neubauer hemocytometer by Trypan blue exclusion.
Six-well plates were seeded with 650,000 cells per well, then
incubated overnight to allow the cells to adhere.
Cells were pre-treated with varying concentrations of glyburide
for 60 min prior to infection (final DMSO concentration 0.1%).
Controls were treated with vehicle (RPMI 1640+Panexin
5%+DMSO 0.1%). The inoculum was prepared by culturing B.
pseudomallei 1026b overnight on Columbia agar with 5% sheep
blood. Colonies were suspended in PBS to OD595 0.25
(,1.26108 cfu/ml). This suspension was then diluted with RPMI
1640 to the required concentration. Inoculum size was verified by
plating serial dilutions onto Columbia agar. Cells were infected
with bacteria for 30 minutes, then washed twice in PBS to remove
extracellular bacteria. RPMI 1640+Panexin 5%+kanamycin
120 mg/ml (,46MIC for this strain to kill extracellular bacteria)
was added to each well. Cell culture supernatants were harvested
24 hours after infection, then stored at 220uC pending assay.
Supernatants were treated with ultraviolet light for 10 minutes
prior to assay in order to sterilize them.
Statistical analyses
Statistical analyses were performed on Stata 11 (StataCorp,
College Station, Texas). Bacterial loads and cytokine concentra-
tions were log-normal. Linear regression was used in preference to
ANOVA because it reports not just a p-value for each group, but
also estimates size of difference and permits interaction testing.
Models were fit by the method of variance-weighted least-squares,
because (unlike ANOVA) the method does not assume homosce-
dasticity (i.e., it was not assumed that variance is the same at each
time point). Responses were not assumed to vary linearly with
time. Separate p-values were reported for each time point only
when justified by a test for interaction. Results from bone marrow-
derived macrophage experiments were analysed by repeated
measures ANOVA. Graphs were plot in GraphPad Prism 5.0c for
Mac OS X (GraphPad Software, San Diego, California).
Identifiers
IL1b (Swiss-Prot identifier P01584 human and P10749 murine),
IL18 (Swiss-Prot ID Q14116 human and P70380 murine); gamma
interferon (Swiss-Prot ID P01579 human and P01580 murine);
caspase 1 (Swiss-Prot ID P29466 human and P29452 murine);
PYCARD (Swiss-Prot ID Q9ULZ3 human and Q9EPB4 murine);
NLRP3 (Swiss-Prot ID Q96P20 human and Q8R4B8 murine);
Streptozocin (PubChem CID 29327), Glyburide/glibenclamide
(PubChem CID 3488). Swiss-Prot online database may be found
at www.uniprot.org.
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Figure 1. Bacterial loads are higher in diabetes. Note. BALF =bronchoalveolar lavage fluid; cfu = colony-forming units; IL = interleukin;
STZ = streptozocin; TNFa= tumor necrosis factor-a. Sixty mice were injected with STZ 60 mg/kg daily for five days (marked by five vertical arrows on
horizontal axis) and compared to 60 controls (treated with citrate buffer pH 4). Only 48 animals were eventually used for infection experiments. A.
Glucose levels in streptozocin-treated animals plateaued 14 days after the first dose of streptozocin was given. The error bars in the graph are ranges.
The horizontal interrupted line is the 16.7 mM cut off used to define diabetes in mice: streptozocin-treated animals treated were not used if their
blood glucose concentrations fell below this level. The graph on the right shows glucose concentrations at time of sacrifice, and the error bars shown
as standard deviations. B. Animals were inoculated with ,66102 cfu B. pseudomallei 4–5 weeks after streptozocin treatment. All mice were treated
with ceftazidime starting 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (8 animals per group per time point). Bacterial loads
were higher in lung, BALF and liver in diabetic animals. Error bars are 95% confidence intervals of the mean. C. When comparing diabetic animals with
controls, no differences were seen in any of the cytokines measured.
doi:10.1371/journal.pntd.0002500.g001
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Results
Diabetes results in delayed bacterial clearance
In our murine model of diabetes blood glucose levels began to
rise one week after the fifth streptozocin dose was given and
reached a plateau after a further week (Figure 1A left). Losses in
the streptozocin-treated group were ,20% with this regimen,
either from complications of the hyperglycemia or because the
animals failed to become diabetic and had to be sacrificed. The
mean blood glucose concentration at sacrifice was 26.7 mM in
diabetic mice compared to 14.9 mM in controls (Figure 1A right).
Mean plasma creatinine concentration was 10.4 mM in streptozo-
cin-treated mice, compared to 6.1 mM in untreated controls
(p=0.05, Welch t-test).
Having established a murine model of diabetes, we proceeded
to examine the influence of diabetes on the pathogenesis of
melioidosis. We infected diabetic mice with ,66102 B. pseudomallei
intranasally. So as to mimic the clinical situation more closely, all
animals received ceftazidime treatment starting 24 h after
inoculation (which is the point at which the animals first become
symptomatic [19]).
Mice were sacrificed after 48, 72 and 96 h (i.e., when animals
showed signs of recovery following ceftazidime treatment) to
determine bacterial loads in lungs and BALF (the primary site of
the infection), liver, spleen and blood (to evaluate dissemination to
distant body sites; Figure 1). We found that bacterial loads were
higher in lung, BALF and liver of diabetic mice when compared to
non-diabetic controls (Figure 1B). There were non-significant
trends to higher bacterial loads in diabetic mice compared to non-
diabetic controls in spleen and blood (data not shown). Having
found that diabetes delays bacterial clearance, we sought to
characterize the host response to infection by measuring cytokine
responses in lung and BALF. We found no differences in cytokine
responses in lung or BALF (IL1b, IL6, TNFa, Figure 1C) despite
the higher bacterial loads in diabetic mice compared to non-
diabetic controls. Since cytokine responses and bacterial loads are
usually correlated, this suggests that a state of relative immuno-
suppression exists in diabetes.
Glyburide does not directly inhibit the growth of B.
pseudomallei
Glyburide is structurally related to the sulfonamides, which are
active against B. pseudomallei. If glyburide inhibits the growth of B.
pseudomallei, then the differences in the inflammatory response we
observed in our clinical study [2] might be explained by a direct
effect on the bacterium and not by an effect on the host response.
In order to exclude the possibility that glyburide directly inhibits
growth of B. pseudomallei, we measured the minimum inhibitory
concentration (MIC) of glyburide, which we found to be
.1000 mM (more than three orders of magnitude higher than
the highest concentration achievable in humans [34]). It therefore
seems unlikely that glyburide is acting via a direct effect on the
bacterium.
Glyburide does not reduce glucose concentrations in the
streptozocin model of diabetes
We proceeded to examine the effect of glyburide on the host
response to melioidosis, using the model of diabetes just described.
The host response is altered by changes in glucose concentra-
tion. The primary action of glyburide in diabetes is to reduce
blood glucose concentration by stimulating insulin secretion by the
b-islet cells of the pancreas. Streptozocin treatment destroys the b-
cells of the pancreas, making animals hyperglycemic and
unresponsive to the action of glyburide. This allowed us to dissect
out the separate effects of glyburide on glucose and on the
inflammatory response. Blood glucose measurements taken at
sacrifice confirmed that in our model of diabetes, blood glucose
concentrations are indeed unaltered by glyburide treatment
compared to vehicle-treated controls (mean glucose 23.9 mM in
glyburide-treated animals versus 21.8 mM in untreated controls,
p=0.40).
Glyburide reduces systemic dissemination of B.
pseudomallei
In this model of melioidosis pneumonia, the primary site of
infection is the lungs. We found no effect of glyburide on bacterial
loads in either lung tissue or in BALF at any of the three time
points measured (p=0.64 and p=0.09 respectively; Figure 2A).
However, glyburide reduced the systemic dissemination of B.
pseudomallei from the lungs to the systemic compartment: bacterial
loads were lower in liver and spleen all three time points measured
in the glyburide treated animals when compared to control
(Figure 2B).
Glyburide is associated with reduced cellular influx into
the lungs
To examine the mechanisms underlying the reduced bacterial
dissemination following glyburide treatment, we next investigated
the influence of glyburide on the pulmonary inflammatory
response during experimental melioidosis.
Melioidosis pneumonia is characterized by a florid influx of cells
into the lungs, and these cells are predominantly neutrophils [19].
Although neutrophils form a critical part of the innate host
response to melioidosis [35], neutrophils may also contribute to
mortality by causing damage to the respiratory tract and have
been implicated in the pathogenesis of the acute respiratory
distress syndrome [36]. In this study, we found that glyburide did
not influence the wet weight of the inflamed lungs or the amount
of protein in BALF (both are markers for capillary leakage;
Figure 3A). We did, however, find that the total number of cells
was reduced in glyburide-treated animals compared to controls.
The majority of cells in this inflammatory infiltrate were
neutrophils, but macrophages were also present in significant
numbers. This difference in cell counts was most apparent at the
48 h time point (Figure 3B).
Glyburide is associated with lower IL1b concentrations in
lung
Glyburide has previously been reported to inhibit inflamma-
some assembly and the key function of the NLRP3 inflamma-
some is the activation and secretion of IL1b [12]. Since IL1b
has been implicated in the recruitment of neutrophils into the
inflamed lung, we hypothesized that glyburide might limit the
influx of cells via a reduction in IL1b release [37,38]. In line
with this hypothesis, we found that in glyburide-treated animals,
concentrations of IL1b were 73.3% lower in lung tissue
48 hours after inoculation compared to controls (p,0.001,
Figure 3C). In lung tissue, IL1b is present in both its mature and
immature forms, and only mature IL1b is secreted into the
alveolar space. IL1b in bronchoalveolar lavage fluid (BALF)
should, therefore, be a better measure of inflammasome
activation than lung tissue. We found that IL1b concentrations
in BALF were 81.7% lower in glyburide-treated mice than
controls (p,0.001, Figure 3C) at 48 hours.
Another role of the NLRP3 inflammasome is the activation and
secretion of IL18, which stimulates natural killer and CD8+ cells to
secrete gamma interferon (IFNc). Inflammasome inhibition would
Glyburide Reduces Dissemination in Melioidosis
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be expected to inhibit the secretion of mature IL18, and in
turn reduce IFNc secretion [39]. Immature IL18 is constitu-
tively expressed at high concentrations in unstimulated cells
[40]. We therefore did not measure IL18 in lung tissue.
Instead, IL18 was measured in BALF, which should represent
the mature secreted form of the cytokine only. At the 48-hour
time point, we found no difference in IL18 concentrations
(geometric mean 251 pg/ml in the glyburide-treated animals
versus 401 pg/ml in control animals, p= 0.17, results not
shown). We also found no differences in IFNc concentrations
in lung or in blood (Figure 4).
Glyburide has no effect on cytokines unrelated to the
inflammasome
In order to determine if the effect of glyburide was isolated to
IL1b, or whether it was a general anti-inflammatory effect, we
assayed the pro-inflammatory cytokines, IL6, TNFa and CXCL5.
The secretion of these three cytokines is unrelated to the
inflammasome. We also considered the possibility that glyburide
might be acting to promote secretion of the anti-inflammatory
cytokine, IL10. Although there were differences in IL6 and TNFa
at the 48 h time point, these differences were small and did not
reach statistical significance. Overall, we found no evidence of an
effect of glyburide on the secretion of CXCL5, IL6, IL10 or TNFa
(Figure S1).
Glyburide reduces IL1b production in bone marrow
derived macrophages
To confirm that that glyburide was acting directly on
macrophage secretion of IL1b, we infected primary bone
marrow-derived macrophages with B. pseudomallei and treated the
cells with varying concentrations of glyburide. In correspondence
with our in vivo data, we found that glyburide reduced IL1b
secretion in a dose-dependent fashion (Figure 5).
Discussion
We have developed a murine model of diabetes and shown that
it is more susceptible to melioidosis than wild-type animals, as
evidenced by higher bacterial loads. This adds to the growing body
of evidence that diabetes per se increases susceptibility to
melioidosis and direct effects of diabetes are not responsible for
the improved survival seen in our previously reported clinical
study [2]. Hodgson et al. report increased mortality from
subcutaneous B. pseudomallei infection in a murine model of
diabetes (BKS.Cg-Dock7(m)+/+Lepr(db)/J mice), and found a
defect in intracellular killing by peritoneal macrophages taken
from diabetic animals compared to non-diabetic animals [9]. The
reason behind the increased susceptibility in diabetes is unclear,
but may relate to delayed or reduced cytokine production in
diabetes [7,8,41].
Figure 2. Bacterial loads in blood, liver and spleen are lower in glyburide-treated mice. Note. BALF= bronchoalveolar lavage fluid;
cfu = colony-forming units. Mice were treated with glyburide or vehicle for seven days prior to inoculation with ,66102 cfu B. pseudomallei. All mice
were treated with ceftazidime starting 24 h after inoculation and continued until sacrifice at 48, 72 or 96 h (eight animals per group per time point).
Error bars are standard deviations. The horizontal interrupted line marks the limit of detection. A. There were no differences found in bacterial loads
at the primary site of infection (lungs and BALF). B. Bacterial loads in glyburide-treated animals were lower in liver and spleen compared to untreated
controls. In blood, there was a trend to bacterial loads being lower in glyburide-treated animals compared to untreated controls, but no p-value is
reported because a large number of points were below the limit of detection (3 cfu/50 ml).
doi:10.1371/journal.pntd.0002500.g002
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Figure 3. Diminished pulmonary leukocyte influx and IL1b production in glyburide-treated mice. Note. BALF =bronchoalveolar lavage
fluid; IL1b= interleukin-1beta. Mice were treated with glyburide or vehicle for seven days prior to inoculation with ,66102 cfu B. pseudomallei. All
mice were treated with ceftazidime starting 24 h after inoculation until sacrifice (eight animals per group per time point). Error bars indicate standard
deviations. A single p-value is reported unless there is evidence from a test of interaction that effects at each time point are different. A. No
differences were found in wet weight of lung or in protein infiltration. B. Cellular infiltrate was reduced in glyburide-treated mice compared to
untreated controls at the 48-hour time point and this difference was seen in both neutrophil and monocyte fractions. C. IL1b concentrations were
lower in glyburide-treated mice compared to untreated controls at the 48-hour time point. This difference was greater in BALF than in lung tissue.
doi:10.1371/journal.pntd.0002500.g003
Figure 4. Glyburide does not influence production of IFNc. Note. IFNc=gamma interferon. Mice were treated with glyburide or vehicle for
seven days prior to intranasal inoculation with ,66102 B. pseudomallei. All mice were treated with ceftazidime starting 24 h after inoculation and
continued until sacrifice (eight animals per group per time point). Error bars indicate standard deviations. A horizontal interrupted line marks the limit
of detection for the assay. No influence of glyburide on IFNc responses in both the pulmonary and systemic compartment was found.
doi:10.1371/journal.pntd.0002500.g004
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We next presented evidence for an anti-inflammatory effect of
glyburide in a diabetic mouse model of melioidosis and this anti-
inflammatory effect appears specific to IL1b. This was supported
by data from stimulated BMDMs, in which glyburide reduced
IL1b secretion in a dose dependent fashion. This is consistent with
the results of previous in vitro and in vivo reports [12,42,43]. To the
best of our knowledge, this is the first time an inhibitory effect of
glyburide on IL1b secretion has been described in any model of
sepsis.
We hypothesized that the effect of glyburide was independent of
its effect on glucose control. This is because in our previously
reported clinical study [2], both patients with hyperglycemia and
patients who were never hyperglycemic had higher mortality rates
than diabetic patients treated with glyburide, suggesting that the
effect we were seeing was unrelated to hyperglycemia, even though
alterations to plasma glucose and insulin concentrations are
themselves well-known to cause changes to the host response [5].
Although the majority of cases of diabetes in Thailand have type 2
diabetes, we therefore elected to use a model of diabetes in which
glucose concentrations were not responsive to glyburide, so as to
answer the question raised by our clinical study.
A limitation of clinical studies of infection has always been that
the interplay between the burden of infection and the inflamma-
tory response has been difficult to tease out. Cytokine levels may
be higher because bacterial burdens are higher, or bacterial
burdens may be higher because of an ineffective innate host
response [44]. Animal studies allow us to control the size of the
initial inoculum and therefore the initial burden of infection. In
this study, we found that bacterial loads in the lungs (the primary
site of infection in our model) were not different between
glyburide-treated and untreated mice. This excludes the possibility
that the differences in IL1b levels in the lungs are due to an effect
of glyburide on the burden of infection in the lungs.
We found that glyburide limits the cellular influx into the lungs,
with effects on both neutrophil and monocyte numbers. Neutro-
phils are a crucial part of the host response to melioidosis [35], but
neutrophils have also been implicated in the pathogenesis of the
acute respiratory distress syndrome [36]. Glyburide was only
associated with a reduction in the magnitude of the neutrophil
response and not its complete ablation (neutrophils are not a
normal constituent of BALF taken from the healthy lung). This
balance between ‘enough’ and ‘too much’ is a common theme in
the pathogenesis of sepsis and its complications [45]. A reduction
in neutrophil influx into the lungs is consistent with our finding
that glyburide is associated with a lower incidence of respiratory
failure in patients with melioidosis [2].
The host response to B. pseudomallei is critically dependent on
cellular immunity [46]. Macrophages, in particular, play a critical
role in initiating the host cytokine response [47–49], in inflamma-
some activation [50] and in recruiting neutrophils to the site of
inflammation (by secreting IL1b [37,51] and chemo-attractants
such as IL8). Paradoxically, B. pseudomallei is a facultative
intracellular pathogen that is capable of parasitizing macrophages
[52–54]. Bacterial burdens in blood, liver and spleen were lower in
our model, suggesting that glyburide reduces bacterial dissemina-
tion. The role of neutrophils and macrophages in the dissemina-
tion of B. pseudomallei is not known, but it is possible to speculate
that the reduced influx of leukocytes into the lungs reduces the
number of cells parasitized by the bacterium and therefore impairs
the ability of B. pseudomallei to disseminate [55].
We found no effect on cytokines unrelated to the inflamma-
some. Specifically, there was no effects seen on CXCL5, IL6, IL10
or TNFa secretion, which is again consistent with previous reports
in the literature [11,12] and rules out a more general anti-
inflammatory effect. In this model, all animals were treated with
full-dose ceftazidime in order to simulate the clinical study that
motivated this experiment [2]. Under this regimen, all animals
showed signs of recovery by 96 hours and the fact that no
differences were seen in cytokine responses at later time points is
therefore not surprising.
Figure 5. Glyburide reduces macrophage IL1b secretion. Note. Gb=glyburide; IL = interleukin. Primary bone marrow-derived macrophages
were infected with B. pseudomallei for 30 min (multiplicity of infection 25 cfu/cell) and incubated with 0 mM (control), 100 mM or 1000 mM glyburide.
IL1b was assayed in supernatant 24 hours later. The graph shows the results of three separate experiments, each linked by solid lines. The limit of
detection for this assay was 55.2 pg/ml.
doi:10.1371/journal.pntd.0002500.g005
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The mechanism by which glyburide is able to inhibit IL1b
secretion is not known. Lamkanfi et al. demonstrated that
glyburide is able to inhibit assembly of the NLRP3 inflammasome
in response to stimulation with lipopolysaccharide (LPS) and
adenosine triphosphate (ATP) [12]. However, when Salmonella
enterica serovar Typhimurium was used as a stimulus, glyburide was
not able to prevent inflammasome assembly, as measured by
caspase 1 cleavage (caspase 1 being a critical component of the
NLRP3 inflammasome) [12]. This suggests that there are
alternative pathways which permit the assembly of the NLRP3
inflammasome. The pathway that glyburide blocks when macro-
phages are confronted by a complex stimulus such as a whole
bacterium is not known.
Our IL1b assay does not distinguish between immature pro-
IL1b and mature cleaved IL1b. The concentrations of IL1b we
report in lung tissue therefore represent a combination of newly
synthesised immature IL1b and mature IL1b. However, only
mature IL1b is secreted into BALF and it therefore a marker of
inflammasome assembly. In our model, glyburide-treatment
reduced IL1b secretion in BALF, but did not block it completely.
This means that there must have been some inflammasome
assembly despite glyburide treatment. Immature IL18 is also
cleaved by the inflammasome, so our finding that inflammasome
assembly is not completely blocked by glyburide in melioidosis is
supported by the fact that we observed a slight but non-significant
reduction in IL18.
We know that inflammasome-activation is necessary for the host
response to B. pseudomallei infection [50], so it seems implausible
that inflammasome-inhibition would be protective in clinical
melioidosis. Although we and others have previously reported that
IL18 protects against B. pseudomallei lung infection [56], Ceballos-
Olvera et al. recently demonstrated that the IL1b response
appeared to be harmful to the host [57]. Our finding that
glyburide seems to preferentially inhibit a potentially deleterious
IL1b response while preserving the IL18 response would therefore
be consistent with a beneficial effect of glyburide in clinical disease.
Our study does not exclude other mechanisms for the action of
glyburide. Aside from an effect on the inflammasome, Hamon et al.
have presented evidence that glyburide may block the secretion of
mature IL1b by an inflammasome-independent mechanism [11].
Glyburide has also been shown to have other anti-inflammatory
effects, including the prevention of ischemic reperfusion injury
[58,59], and an enhancement of intracellular killing of Leishmania
parasites [60].
In conclusion, we have replicated our clinical finding that
glyburide treatment exerts beneficial effects in melioidosis [61],
using an experimental model of melioidosis in diabetic mice. We
now show for the first time in any model of sepsis that glyburide
acts as an anti-inflammatory agent by reducing IL1b secretion,
cellular infiltration into the lungs and bacterial dissemination to
distant organs. Although glyburide has previously been shown to
prevent IL1b maturation and secretion by inhibiting inflamma-
some assembly, the presence of still detectable levels of IL1b in
BALF, coupled with smaller-than-expected effects on IL18 and
IFNc, means inflammasome inhibition is incomplete, or that this
may only explain partly the mechanism by which glyburide acts in
the context of melioidosis.
Supporting Information
Figure S1 Glyburide does not influence production of
non-inflammasome cytokines in pulmonary B. pseudo-
mallei infection. Note. BALF=bronchoalveolar lavage fluid;
IL= interleukin; TNFa= tumor necrosis factor-alpha. Mice were
treated with glyburide or vehicle for 7 days prior to inoculation
with ,66102 cfu B. pseudomallei. All mice were treated with
ceftazidime starting 24 h after inoculation until sacrifice (8 animals
per group per time point). Error bars indicate standard deviations.
A single p-value is reported for each cytokine unless there is
evidence from a test of interaction that effects at each time point
are different. A horizontal interrupted line marks the limit of
detection for the assay. Glyburide did not influence the production
of IL6, IL10, CXCL5 and TNFa in the systemic or pulmonary
compartment.
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